Loading stock data…
$45.13-3.42 (-7.04%)
Pulse Biosciences, Inc.
Pulse Biosciences, Inc. in the Healthcare sector is trading at $45.12 with a market capitalization of $3.5B. Wall Street consensus targets $62.33 (6 analysts), implying a +38.1% move over the next 12 months. The stock is currently 23% below its 52-week high of $58.90, remaining 54.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $434,000↑ | $401,000↑ | $264,000↑ | $86,000 | $0 |
| Gross Profit | $161,000↑ | $31,000↑ | $4,000↑ | -$193,000 | $0 |
| Operating Income | -$25.27M↓ | -$19.15M↓ | -$18.25M↑ | -$20.37M↓ | -$20.27M |
| Net Income | -$24.66M↓ | -$18.58M↓ | -$17.43M↑ | -$19.39M↓ | -$19.17M |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft ...